{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.8","upperLimit":"272.9","value":"128.9"},{"groupId":"OG001","lowerLimit":"48.8","upperLimit":"193.9","value":"62.2"},{"groupId":"OG002","lowerLimit":"18.9","upperLimit":"97.0","value":"51.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion","title":"CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1","type":"SECONDARY","unitOfMeasure":"µmol·h/L"}